Adam de Havenon

Once-weekly glucagon-like peptide-1 receptor agonists vs dipeptidyl peptidase-4 inhibitors: cardiovascular effects in people with diabetes and cardiovascular disease

J. Rajpura, Yuanjie Liang, Josh Noone, 2023, Cardiovascular Diabetology.